Cancer Cell Market Size, Trends and Forecast 2033

Technological Innovations and Safety Features to Drive Cancer Cell Market to USD 24.4 Billion by 2033 at 10.3% CAGR – Coherent Market Insights

Global Cancer Cell Market – Driver

Rising Cancer Incidence and Treatment Demand

The increasing number of cancer patients is expanding demand for chemotherapy, immunotherapy, targeted drugs, cell-based treatments, and diagnostic testing. In 2026, approximately 2,114,850 new cancer cases and 626,140 cancer deaths are projected in the U.S., with incidence continuing to rise for several common cancers. (Source: American Cancer Society)

Rapid Development of Precision Oncology Therapies

Greater understanding of cancer-cell mutations is supporting treatments designed for specific molecular abnormalities. In July 2026, the FDA approved zidesamtinib for previously treated ROS1-positive non-small cell lung cancer and granted traditional approval to selpercatinib for advanced solid tumors carrying RET gene fusions. (Source: U.S. FDA)

Increasing Adoption of Biomarker and Liquid-Biopsy Testing

Biomarker testing allows clinicians to identify residual cancer cells and select suitable patients for precision treatments. On May 15, 2026, the FDA approved Signatera CDx, a circulating tumor DNA test used to identify muscle-invasive bladder cancer patients who may benefit from adjuvant atezolizumab therapy. (Source: U.S. FDA)

Global Cancer Cell Market – Opportunity

Continued Introduction of Therapies for Difficult-to-Treat Cancers

High unmet need in aggressive and treatment-resistant cancers is encouraging pharmaceutical research and commercialization. For instance, in May 2026, the U.S.FDA approved datopotamab deruxtecan for unresectable or metastatic triple-negative breast cancer and expanded trastuzumab deruxtecan into two HER2-positive early-stage breast cancer indications. (Source: U.S.FDA)

Expansion of Precision and Cell-Based Cancer Therapies

The development of personalized, biomarker-guided and immune-cell-based therapies presents a major growth opportunity for the global cancer cell market. These technologies enable treatments to target specific cancer-cell mutations and improve outcomes in patients who do not respond adequately to conventional therapies. For instance, in June 2026, the U.S. FDA approved Tregzi, an allogeneic regulatory T-cell-based immunotherapy, for use with matched-donor stem-cell transplantation in adults with hematological malignancies, demonstrating the commercial advancement of engineered cell therapies. Furthermore, the National Cancer Institute reported in 2026 that pembrolizumab, which emerged from checkpoint-inhibitor research, had become an effective treatment option across 43 cancer types. Continued development of cell therapies, companion diagnostics and molecular testing can therefore expand treatment into solid tumors, rare cancers and therapy-resistant patient groups. (Source: U.S.FDA)

Global Cancer Cell Market – Trends

Increasing Adoption of Combination and Perioperative Therapy

Cancer treatment is increasingly moving into earlier disease stages through therapies administered before and after surgery. In July 2026, the FDA approved pembrolizumab with enfortumab vedotin as neoadjuvant and adjuvant treatment for adults with muscle-invasive bladder cancer.

Growing Shift Toward Biomarker-Guided Precision Oncology

Cancer treatment is increasingly based on specific genetic changes within tumor cells rather than cancer location alone. In February 2026, the FDA approved zongertinib for advanced non-small cell lung cancer carrying HER2-activating mutations, as identified through an FDA-authorized test.

Rising Adoption of Liquid Biopsy and ctDNA Monitoring

Circulating tumor DNA testing is gaining importance for detecting molecular residual disease, monitoring recurrence risk and selecting treatment. In May 2026, the FDA approved Signatera CDx to identify ctDNA-positive bladder cancer patients who may benefit from adjuvant atezolizumab following surgery.

Cell Therapies Are Expanding Beyond Blood Cancers

CAR-T and other engineered immune-cell therapies are increasingly being investigated for solid tumors. A 2026 ClinicalTrials.gov study is evaluating B7-H3-directed CAR-T cells in children and young adults with relapsed or treatment-resistant solid cancers expressing the B7-H3 marker.

Rapid Expansion of Antibody–Drug Conjugates

Antibody–drug conjugates are increasingly used to deliver cytotoxic agents directly to cancer cells expressing specific surface proteins. In May 2026, the FDA approved datopotamab deruxtecan for metastatic triple-negative breast cancer and expanded trastuzumab deruxtecan into HER2-positive early-stage breast cancer treatment.

Increasing Use of AI and Spatial Tumor Profiling

Artificial intelligence is being integrated with pathology, imaging, genomics and spatial proteomics to analyze tumor-cell heterogeneity and predict treatment response. In 2026, the National Cancer Institute dedicated its Data Science Seminar Series to AI applications in cancer research and precision care.

Growth of Nanoparticle-Enabled Cancer Immunotherapy

Nanotechnology is supporting targeted drug delivery, tumor imaging and immune-system activation while potentially reducing systemic toxicity. At its March 2026 annual meeting, the NCI highlighted neoantigen mRNA platforms, in-situ cancer vaccination and immune-modulating nanocarriers as emerging translational approaches.

Global Cancer Cell Market, by Cancer Cell Type (Carcinomas, Sarcomas, Leukemia, and Others), by Application (Chemotherapy, Radiation Therapy, Immunotherapy, Hormone Therapy, Targeted Drug Therapy, and Others), by End User (Hospitals & Clinics, Specialty Clinics, and Diagnostic Laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 12.8 Bn in 2026 and is expected to exhibit a CAGR of 10.3% during the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.

Key companies focusing on approvals from regulatory bodies for novel treatment of cancers such as breast cancer and others is expected to drive the global cancer cell market. For instance, in 2019, Novartis, announced to receive the U.S. Food and Drug Administration (FDA) approval for Piqray (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated advanced or metastatic breast cancer.

Browse 32 Market Data Tables and 32 Figures spread through 175 Pages and in-depth TOC on “Global Cancer Cell Market, by Cancer Cell Type (Carcinomas, Sarcomas, Leukemia, and Others), by Application (Chemotherapy, Radiation Therapy, Immunotherapy, Hormone Therapy, Targeted Drug Therapy, and Others), by End User (Hospitals & Clinics, Specialty Clinics, and Diagnostic Laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”

To know the latest trends and insights prevalent in the global cancer cell market, click the link below:

https://www.coherentmarketinsights.com/market-insight/cancer-cell-market-4338

Key Takeaways of the Global Cancer Cell Market

The global cancer cell market is expected to exhibit a CAGR of 10.3% during the forecast period, owing to key companies focusing on research and development for the treatment of cancer.
Among cancer cell type, Leukemia segment is estimated to hold major market share of 43.4% in the global cancer cell market during the forecast period, due to increasing incidence of leukemia. For instance, in 2026, the National Cancer Institute’s SEER program estimates 67,790 new leukemia cases and 23,910 leukemia-related deaths in the U.S. in 2026, demonstrating a substantial disease burden that supports demand for leukemia diagnosis, treatment, and disease-management solutions. (Source: SEER)
Among application, chemotherapy segment is estimated to hold major market share in the global cancer cell market during the forecast period, owing to chemotherapy exhibiting high efficiency and safety of patients while treating cancers. Chemotherapy is expected to hold the largest market share of 34.9% in 2026, owing to its broad use across multiple cancer types, either alone or alongside surgery, radiotherapy, immunotherapy, and targeted treatments. In 2026, the U.S. is projected to record 321,910 new breast cancer cases, 229,410 lung and bronchus cancer cases, and 158,850 colorectal cancer cases—approximately 710,170 cases combined. The National Cancer Institute continues to include chemotherapy within established treatment protocols for these high-burden cancers, supporting sustained demand despite advances in precision oncology. (Source: American Cancer Society)
Key players operating in the global cancer cell market include Abbott Laboratories, Novartis International AG, Arcellx, Autolus Therapeutics, Kite Pharma, Cellectis, Celyad Oncology, Crescendo Biologics Limited, GammaDelta Therapeutics Ltd., Bio-Rad Laboratories Inc, QIAGEN Inc, Thermo Fisher Scientific, Merck Millipore, Siemens Healthineers AG, and GE Healthcare.

Recent Developments

On July 22, 2026, the U.S. FDA approved Nuvalent’s Jideytro (zidesamtinib) for adults with advanced ROS1-positive non-small cell lung cancer previously treated with a ROS1 inhibitor. The precision therapy produced a 44% overall response rate, with 69% of responders maintaining responses for at least 12 months. (Source: U.S.FDA)
On July 10, 2026, the U.S.FDA approved Keytruda or Keytruda Qlex combined with Padcev before and after surgery for muscle-invasive bladder cancer. The regimen significantly improved event-free and overall survival compared with neoadjuvant chemotherapy, highlighting the movement of immunotherapy and antibody–drug conjugates into earlier cancer stages. (Source: U.S.FDA)
On June 30, 2026, the U.S.FDA approved Orca Bio’s Tregzi, an allogeneic regulatory T-cell-based immunotherapy used with matched-donor stem-cell transplantation for adults with hematological malignancies. The treatment uses separately engineered stem, regulatory T-cell and conventional T-cell components, representing an important innovation in precision cellular therapy. (Source: U.S.FDA)